Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential role of non-covalent BTK inhibitors (BTKis) in mitigating covalent BTKi resistance. Dr Jain notes that non-covalent BTKis, such as pirtobrutinib, have shown favorable safety profiles and efficacy, particularly in patients who have failed covalent BTKis. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть